IOBT

IO Biotech, Inc. Common Stock
Data: 2026-01-30
$0.2901
Price
-5.93%
Change
$2.79
52W High
$0.2053
52W Low

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Quick Stats
Jan 30, 2026

46.1

AI Score

HOLD

0.09

Volume Ratio

Mar 04, 2026

Next Earnings

15

+ve Days (30d)

15

-ve Days (30d)

IOBT Stock Summary

Last updated Jan 30, 2026

IOBT is currently trading at $0.2901, positioned below its 200-day moving average of $1.14, suggesting bearish momentum. The stock has a 52-week range of $0.2053 to $2.79.

Technical Analysis: The 50-day moving average stands at $0.62, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 36.851, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.305, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates IOBT at 46.1/100 with a HOLD recommendation.

IOBT (IO Biotech, Inc. Common Stock) Indicators

Last updated Jan 30, 2026

Indicator Value
RSI(14) 36.851
CMF (20) 0.305
ROC (10) -43.779
ADX (14) 33.85
Indicator Value
MACD (12,26,9) -0.099
AROONOSC (14) -50.0
WILLAMS %R (14) -77.871
MFI (14) 91.577
IOBT Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

IOBT Price vs Max Options Open Interest
IOBT Max Change In Options Open Interest

IOBT Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

IOBT Daily Out of Money Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

IOBT Daily In the Money Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

IOBT Most Active Options by Volume(near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

IO Biotech, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

IOBT Moving Averages Analysis

IOBT (IO Biotech, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Jan 30, 2026

Days MA
10 0.36
20 0.47
30 0.53
50 0.62
100 0.81
200 1.14

IOBT Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 22.8 million
Earnings/Share ($) -1.34
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -0.88
EPS Estimate Next Year ($) -0.36
WallStreet Target Price ($) 2.18
Most Recent Quarter